Safety and immunogenicity of PENNVAX-G DNA prime administered by biojector 2000 or CELLECTRA electroporation device with modified vaccinia Ankara-CMDR boost

Julie A. Ake*, Alexandra Schuetz, Poonam Pegu, Lindsay Wieczorek, Michael A. Eller, Hannah Kibuuka, Fredrick Sawe, Leonard Maboko, Victoria Polonis, Nicos Karasavva, David Weiner, Arthur Sekiziyivu, Josphat Kosgei, Marco Missanga, Arne Kroidl, Philipp Mann, Silvia Ratto-Kim, Leigh Anne Eller, Patricia Earl, Bernard MossJulie Dorsey-Spitz, Mark Milazzo, G. Laissa Ouedraogo, Farrukh Rizvi, Jian Yan, Amir S. Khan, Sheila Peel, Niranjan Y. Sardesai, Nelson L. Michael, Viseth Ngauy, Mary Marovich, Merlin L. Robb

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and immunogenicity of PENNVAX-G DNA prime administered by biojector 2000 or CELLECTRA electroporation device with modified vaccinia Ankara-CMDR boost'. Together they form a unique fingerprint.

Medicine & Life Sciences